Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2013

View Archived Issues

Velocity Pharmaceutical Development announces collaboration and VPD-737 IND

Tyrosine-protein kinase inhibitors disclosed by Daiichi Sankyo

Novel Bcl-2 inhibitors reported by French researchers

Ambra-1 expression is linked to NRAS/BRAF mutational status in melanoma

MacroGenics doses first patient in phase I MGA-271 trial

OSI Pharmaceuticals presents new compounds with promise in ovarian cancer models

BYM-338 receives FDA breakthrough therapy designation

Adimab establishes new collaborations with Innovent and Celgene

Varinel synthesizes novel iron chelators for neurodegenerative disorders

Novel hRAD51 protein expression inhibitors disclosed by Eisai

Otonomy's OTO-201 reduces treatment failure in subjects undergoing ear tube placement surgery

Toray Industries divulges new SEH inhibitors for hypertension

DiaMedica enrolls final patient in DM-199 clinical trial

Eisai files petition in federal court seeking DEA scheduling of Fycompa

FDA grants orphan drug designation to Alnylam's RNAi therapeutic for hemophilia A

RedHill completes European regulatory meetings for Crohn's disease therapeutic

Mutations in TGF-beta predispose to allergic phenotypes in humans

Oncopeptides commences phase II study of melflufen in multiple myeloma

PDI signs agreement to commercialize molecular diagnostic tests

Membrane active chelators for the treatment of malaria and African trypanosomiasis

FDA grants orphan drug status to dantrolene sodium

Australian team prepares new L-type calcium channel compounds

Orphan drug status granted to deflazacort

FDA grants orphan drug status for ruxolitinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...